|
Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine Clinical research trials and Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine. Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine clinical trial. Human subjects often get the best healthcare possible for their Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine  Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine
Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine
For Condition: HIV Infection
Status: Completed
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Recent studies have shown that patients receiving state-of-the-art treatment for HIV infection (highly active antiretroviral therapy, or HAART) show discordant responses to therapy-that is, they improve both clinically and immunologically (increased CD4 immune cell counts), but their levels of HIV in the blood do not drop. This study will examine blood samples taken from HIV-infected children treated with 2',3'-dideoxyinosine (didanosine, or ddI) in an earlier NCI study to determine if these patients had similar discordant responses to therapy. If so, the study will also examine how these factors may be predictive of disease progression and survival. Investigators will measure HIV levels in blood specimens from children previously enrolled in NCI protocol 88-C-0129. The measurements will be done in specimens drawn before initiation of treatment with ddI and at various times during the course of treatment. The viral responses to therapy will then be correlated with short- and long-term clinical and immunologic outcomes. In addition, researchers will examine these patients' blood samples for additional factors recently discovered to potentially influence disease progression. They include selenium levels and certain genetic factors. A better understanding of discordant responses to therapy will help physicians determine the best treatment option in situations where therapy results do not show uniform benefit. This protocol involves the scientific examination of laboratory specimens only and is not a clinical study open to patient enrollment.
Details: This study will examine clinical and immunologic data and HIV-1 RNA levels in banked serum specimens from HIV-infected pediatric patients previously enrolled on NCI protocol 88-C-0219, a phase I/II study of 2', 3'-dideoxyinosine (ddI). In the original study serum p24 antigen was used as the direct measurement of viral quantitation. Advances in understanding of HIV pathophysiology have demonstrated that HIV-1 RNA level as measured by quantitative RNA PCR is a far superior molecular tool for assessing viral replication and burden in vivo. Analysis of clinical, HIV-1 RNA and CD4 responses will be performed to identify patients with discordant surrogate marker responses to therapy, defined as: improvement in immunologic parameters in the setting of virologic non-response or failure. Correlation will then be made with short and long term clinical outcomes. Following the initial analysis to identify patients with discordant responses, selenium levels, viral genotypic and phenotypic profiles of resistance to ddI, and in vitro viral fitness will be examined. These biologic parameters have recently been determined to potentially play an important role in clinical, immunologic and virologic HIV-related outcomes. Parameters will be examined in subsets of patients with the following surrogate marker response profiles: a.) immunologic and virologic responders; b.) immunologic and virologic non-responders; and c.) discordant immunologic and virologic responders. Specimens from the ddI monotherapy study were chosen for this analysis because a substantial body of clinical and immunologic data is available on patients up to 7 years.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Prior enrollment on NCI protocol 88-C-0219, a phase I/II study of 2',3'- dideoxyinosine (ddI) in children with human immunodeficiency virus infection. Informed consent for participation in 88-C-0219 clinical trial. Adequate available clinical and immunologic data and banked blood specimen components obtained during implementation of the protocol.
Total Enrollment: 82
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 000130; 00-C-0130
Study Start Date: May 9, 2000
Record last reviewed: April 17, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00026676
Other Hiv Infection Studies:
1. A Medication Adherence Intervention for HIV Infected Veterans
2. Genetically Modified Lymphocytes to Treat HIV-infected Identical Twins - Study Modifications
3. Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral Therapy
4. Safety and Anti-HIV Activity of Capravirine Alone and in Combination with Other Anti-HIV Drugs
5. Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan
Related Studies:
Other HIV Infection Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Correlation of HIV Levels with Clinical and Immunologic Outcome in Children Treated with Didanosine
|
|
|
|
|
|
|
|
